ArticleTransplantation2017
Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients.
Article in Transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- Association of donor-specific antibodies with adverse outcomes in solid organ transplantation: A systematic review and meta-analysis of 69 studies.Frontiers in immunology · 2025Pooled it
- Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis.PLoS medicine · 2018Pooled it
- Plasma exchange combined with anti-B-cell therapy enables comparable outcomes between DSA-positive and DSA-negative aplastic anemia after haplo-HSCT: a propensity-score-matched cohort study.Annals of hematology · 2026Article
- Prevalence of non-HLA antibodies and their association with FIB-4 index-based fibrosis risk in pediatric liver transplant recipients with long-term graft survival (>10 years).Frontiers in immunology · 2026Article
- Contribution of long-lived plasma cells to antibody-mediated allograft rejection.Clinical transplantation and research · 2024Review
- Chimerism-Mediated Tolerance in Intestinal Transplantation.Gastroenterology clinics of North America · 2024Review
- Dynamic establishment and maintenance of the human intestinal B cell population and repertoire following transplantation in a pediatric-dominated cohort.Frontiers in immunology · 2024Article
- Dynamic establishment and maintenance of the human intestinal B cell population and repertoire following transplantation.medRxiv : the preprint server for health sciences · 2023Article
- Liver Inclusion Appears to Be Protective Against Graft Loss-Due-to Chronic But Not Acute Rejection Following Intestinal Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Afucosylation of HLA-specific IgG1 as a potential predictor of antibody pathogenicity in kidney transplantation.Cell reports. Medicine · 2022Article
- Immunosuppression Regimens for Intestinal Transplantation in Children.Paediatric drugs · 2022Review
- Antibody-removal therapies for de novo DSA in pediatric intestinal recipients: Why, when, and how? A single-center experience.Frontiers in pediatrics · 2022Article
- Enhanced virtual crossmatch in intestinal transplantation: association with outcomes and application in practice.Korean journal of transplantation · 2021Article
- Non-HLA AT1R antibodies are highly prevalent after pediatric intestinal transplantation.Pediatric transplantation · 2021Article
- B cells in transplant tolerance and rejection: friends or foes?Transplant international : official journal of the European Society for Organ Transplantation · 2020Review
- Predicting Humoral Alloimmunity from Differences in Donor and Recipient HLA Surface Electrostatic Potential.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Characterization of T cell immunophenotypes in intestinal transplantation: A pilot study.Transplant immunology · 2018Article
- Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.The Journal of clinical investigation · 2017Review
- Small intestine transplant immunologic risk assessment: More data is needed.Intestinal Failure (New York, N.Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRejection remains the leading cause of allograft loss, and a major barrier to improving long-term outcomes after intestinal transplantation. Our aim is to define the prevalence and investigate the role of donor-specific antibody (DSA) on intestinal graft outcomes.
methodsThe study includes 109 transplants performed in 95 recipients at a single center. Patients were screened for DSA pretransplant, monitored regularly posttransplant and when clinically indicated using the single-antigen bead Luminex assay. Standard induction immunosuppression was with interleukin-2 receptor antagonists, and antithymocyte globulin in high-risk recipients. Maintenance regimens were tacrolimus-based.
resultsPretransplant DSA was detected in 12 (11%) recipients with 50% continuing to have circulating antibodies posttransplant. An additional 24 (25%) patients developed de novo DSA, and of these, 71% had persistent antibodies. Recipients with preformed DSA demonstrated elevated risks of early graft failure, whereas those with de novo DSA experienced accelerated graft loss once DSA was detected, reaching a 28% failure rate within 2 years. HLA-DQ mismatch is a significant risk factor for de novo DSA emergence, whereas the persistence of antibodies is predicted by DSA strength and specificity. Although inclusion of the liver in the intestinal allograft imparts an immunological advantage against rejection-related graft loss, this protective effect was lost among recipients with persistent DSA.
conclusionsThe presence of DSA is associated with inferior graft outcomes among intestinal transplant recipients. An enhanced understanding of the mechanisms by which DSA causes allograft injury, and effective strategies targeting humoral immune reactivity are needed to improve long-term intestinal graft outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.